Research programme: therapeutic antibodies - Jiangsu Hengrui/Shanghai ChemPartner
Latest Information Update: 16 Jul 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Developer Jiangsu Hengrui Medicine Co.; ShangPharma
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in China (Parenteral)
- 15 Sep 2011 Early research in Undefined indication in China (Parenteral)